The Role of the Blood-Brain Barrier during Venezuelan Equine Encephalitis Virus Infection by Schafer, A. et al.
JOURNAL OF VIROLOGY, Oct. 2011, p. 10682–10690 Vol. 85, No. 20
0022-538X/11/$12.00 doi:10.1128/JVI.05032-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
The Role of the Blood-Brain Barrier during Venezuelan Equine
Encephalitis Virus Infection
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Venezuelan equine encephalitis (VEE) virus is a mosquito-borne alphavirus associated with sporadic
outbreaks in human and equid populations in the Western Hemisphere. After the bite of an infected mosquito,
the virus initiates a biphasic disease: a peripheral phase with viral replication in lymphoid and myeloid tissues,
followed by a neurotropic phase with infection of central nervous system (CNS) neurons, causing neuropa-
thology and in some cases fatal encephalitis. The mechanisms allowing VEE virus to enter the CNS are
currently poorly understood. Previous data have shown that the virus gains access to the CNS by infecting
olfactory sensory neurons in the nasal mucosa of mice. However, at day 5 after inoculation, the infection of the
brain is multifocal, indicating that virus particles are able to cross the blood-brain barrier (BBB). To better
understand the role of the BBB during VEE virus infection, we used a well-characterized mouse model system.
Using VEE virus replicon particles (VRP), we modeled the early events of neuroinvasion, showing that the
replication of VRP in the nasal mucosa induced the opening of the BBB, allowing peripherally administered
VRP to invade the brain. Peripheral VEE virus infection was characterized by a biphasic opening of the BBB.
Further, inhibition of BBB opening resulted in a delayed viral neuroinvasion and pathogenesis. Overall, these
results suggest that VEE virus initially enters the CNS through the olfactory pathways and initiates viral
replication in the brain, which induces the opening of the BBB, allowing a second wave of invading virus from
the periphery to enter the brain.
Venezuelan equine encephalitis (VEE) virus is an arthro-
pod-borne single-stranded positive-sense RNA virus associ-
ated with periodic epidemics and epizootics in the Western
Hemisphere. In equines, VEE virus causes a wide spectrum of
disease ranging from unapparent illness to acute encephalitis
(28). While enzootic strains cause minimal clinical illness in
equines, disease induced by epizootic strains can be severe,
causing high mortality (19% to 83%). In humans, the devel-
opment of encephalitis appears in approximately 4% of cases
with an overall case mortality rate of 1 to 2% (28).
Unlike the development of the disease in humans, inocula-
tion of mice with a low dose of VEE virus into the rear footpad
results in a rapidly progressing disease culminating in 100%
mortality due to encephalitis. Virus replication in the draining
lymph node (DLN) is detectable within 3 h. By 12 h, viremia is
at or near its peak level; by 18 h, virus is replicating in virtually
every lymphoid tissue, and a marked leucopenia is evident.
Virus replication in the brain is detectable in olfactory tracts by
30 h postinfection (hpi), presumably having crossed from the
circulation into olfactory sensory neurons (OSN) in the nasal
olfactory neuroepithelium and hence along olfactory nerve
tracts to the central nervous system (CNS). Encephalitis and
death ensues 7 to 10 days after infection (3, 6, 11, 13, 21, 25).
Viral invasion and successful infection of the CNS is an
important step in the life cycle of neurotropic viruses (14). The
CNS is an immune-privileged site, protected by the blood-
brain barrier (BBB) (5). The BBB is interposed between the
circulatory system and the CNS and maintains the microenvi-
ronment of the brain (5, 18). The BBB is formed by brain
capillary endothelial cells (BCEC), which line the cerebral
microvessels. BCEC are specialized endothelial cells with tight
junctions that make the lining of brain capillaries 50 to 100
times tighter than those in the periphery. The integrity of the
BBB is maintained by the interaction of microvessel walls with
perivascular endfeet of astrocytes and the continuous secretion
of astrocytic-derived factors, such as transforming growth fac-
tor- (TGF-), glia-derived growth factor (GDNF), and basic
fibroblast growth factor (bFGF) (1).
Pathogens have evolved several strategies that allow them to
cross the BBB successfully and to gain access to the CNS.
Herpes simplex virus and rabies virus spread transneurally
from the site of entry and reach the CNS via axonal and/or
retrograde transport. Other viruses cause viremia and use var-
ious mechanisms to cross the BBB and gain access to the CNS,
including paracellular entry while the BBB is compromised,
epithelium-mediated transcytosis, transmigration within in-
fected leukocytes, or the infection of olfactory sensory neurons
with subsequent axonal spread (22). In addition to these path-
ways, several host factors are associated with pathogen neuro-
invasion: Toll-like receptor 3 (TLR-3), intercellular adhesion
molecule 1 (ICAM-1), the matrix metalloproteinase 9 (MMP-
9), interleukin-1 (IL-1), and tumor necrosis factor alpha
(TNF-) promote the ability of West Nile virus (WNV) to
cross the BBB (7, 26, 27).
For VEE virus, the olfactory neuroepithelium has been sug-
gested as a primary entryway into the CNS (6, 21). In previous
studies, viral replication was detectable at 24 to 30 h in OSN of
the olfactory bulbs (OB) after footpad inoculation. At 30 to 36
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hpi, in situ hybridization signal was detected in the olfactory
cortex. Between 3 and 5 days postinfection (dpi), viral replica-
tion in the brain was multifocal and localized in association
with brain capillaries, indicating involvement of the BBB (6, 21).
Additionally, we previously demonstrated opening of the BBB
after intracerebral inoculation of VEE virus replicon particles
(VRP) and subsequent viral replication in the brain (23).
In this study, the role of the BBB during peripheral VEE
virus infection was evaluated using VRP to model the early
events of VEE viral neuroinvasion. VRP undergo only a single
round of replication with no propagation and spread, as
the replicon genomes do not encode the structural genes of the
virus (19). Thus, when inoculated in vivo, VRP infect the same
first cell as are infected by the complete virus, but because the
infection cannot spread, VRP provide a valuable tool to model
the earliest events in neuropathogenesis.
Using infection with VEE 3000 (V3000) and VRP we dem-
onstrated that (i) VRP infection of OSN induces opening of
the BBB, (ii) this allows direct entry of circulating VRP into
the brain, (iii) peripheral inoculation of V3000 itself results in
BBB opening, and (iv) inhibition of BBB opening significantly
reduces neuroinvasion of V3000 while delaying V3000 morbid-
ity and reducing mortality.
MATERIALS AND METHODS
Virus and VRP. The isolation of wild-type VEE virus, Trinidad donkey strain,
and the generation of the molecular clone pVR3000 (V3000) has been described
previously (3). Virus stocks were generated by in vitro transcription of the
linearized cDNA clone using a T7-specific mMessage mMachine kit (Ambion)
and electroporating the generated transcripts into BHK-21 cells. To harvest
virus, culture supernatants were collected 18 h postelectroporation and clarified
by centrifugation at 3,000 rpm for 20 min at 4°C. Virus stocks were stored as
single-use aliquots at 80°C. Viral titers were determined by plaque assay on
BHK-21 cells as previously described (24).
VRP genomes consist of the VEE virus 5-replicase, the 26S promoter, and a
transgene such as enhanced green fluorescent protein (eGFP). Briefly, appro-
priate replicon and helper RNAs, for capsid and the glycoproteins, were elec-
troporated into BHK-21 cells, and the supernatants containing VRP were har-
vested. After confirming the absence of propagating recombinant virus by
passage of a sample on BHK-21 cells and examination of cytopathic effect (CPE),
VRP preparations were concentrated by centrifugation, and titers were deter-
mined by indirect immunofluorescence in BHK-21 cells using a polyclonal anti-
body to nsP2. All of the VRP used in this study expressed eGFP as the transgene,
unless otherwise indicated, and were packaged in the wild-type V3000 envelope
as previously described (23).
Animal studies. Female, 4- to 8-week-old BALB/c mice were purchased from
Charles River. All experimental procedures in mice using wild-type V3000 were
performed in a biosafety level 3 (BSL-3) animal facility following at least a 7-day
acclimatization period, such that mice were approximately 6 to 10 weeks old
when used for infection studies. After mice were anesthetized with a ketamine-
xylazine mixture, they were inoculated, if not otherwise indicated, in the left rear
footpad with 103 PFU V3000 (102 PFU in MMP-9 inhibition experiments) virus
in diluent (endotoxin-free phosphate-buffered saline [PBS] supplemented with
1% donor calf serum, Ca2, Mg2; total volume, 10 l). Control (mock) animals
were inoculated with 10 l of diluent alone. After inoculation, V3000-infected
animals were monitored and assessed daily for development of disease signs and
weight loss. Mice that lost more than 20% of their starting body weight or
became moribund were euthanized according to University of North Carolina
(UNC) Institutional Animal Care and Use Committee (IACUC) guidelines (4).
All experimental manipulations of mice with VRP were performed under BSL-2
conditions as previously described (23). For intranasal (i.n.) inoculations, mice
were restrained and 2  106 IU VRP in 10 l diluent, or diluent alone as control,
were applied in each nostril.
MMP-9 inhibition. Groups of mice were injected intraperitoneally (i.p.) with
either 2 mg per mouse GM6001 (Ilomostat; US Biological) or with the vehicle,
dimethyl sulfoxide (DMSO), prior toV3000 infection (102 PFU into the rear
footpad). Treated mice then received 2 mg of GM6001, 3 h prior to V3000
infection and on day 1 and day 3, or for control animals, DMSO alone (15).
Evaluation of BBB permeability. At selected time points, mice were injected
i.p. with 800 l of 1% Evans blue dye in 1 PBS, and uptake of the dye into the
brain was evaluated as described previously (23).
Virus titers. To quantify V3000 titers in vivo, infected or mock-infected ani-
mals were deeply anesthetized, bled, and perfused with PBS as previously de-
scribed (4). After euthanasia, tissues and serum were collected and frozen at
80°C and then later thawed, homogenized, and used to infect BHK-21 cells in
a standard plaque assay.
RNA isolation, real-time PCR, and analysis. Total RNA was isolated from
brain tissues of V3000-infected, VRP-inoculated, and mock-treated animals with
a Qiagen lipid tissues minikit. Total RNA from corresponding serum samples
were isolated with a QIAamp DNA blood minikit. Expression levels of different
genes were measured by quantitative real-time PCR (RT-PCR) as previously
described (23). Briefly, cDNAs were synthesized from mRNA by reverse tran-
scription with oligo(dT). RT-PCR was then performed with TaqMan gene ex-
pression assays (Applied Biosystems) containing gene-specific primers, probes,
and an ABI Prism 7000 real-time PCR system. For analysis, all expression levels
of target genes were normalized to that of the housekeeping gene for glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) based on the CT. Gene expres-
sion values were then calculated based on the CT method, by using the mean
from three untreated mice as the calibrator to which all other samples were
compared. Relative expression levels were determined by using the following
formula: relative expression 	 2CT.
Immunohistochemistry. Mice were inoculated i.n. with VRP as described
above. At day 2 postinoculation, mice were perfused with 2% paraformaldehyde
(PFA), and brains were removed, as described previously (23). Harvested brains
were placed in 4% PFA overnight at 4°C, rehydrated in 30% sucrose for 24 h, and
frozen in Tissue-Tek OCT compound with a histobath. Tissues were sectioned at
10 m with a cryostat and mounted on poly-L-lysine-coated slides. CNS neurons
were stained with anti-NeuN (neuronal nuclei, clone 60; Chemicon) and MMP-9
with anti-MMP-9 (goat IgG; R&D Systems). After reaction with secondary
antibodies (biotinylated anti-mouse and anti-goat immunoglobulin G; Vector),
the proper fluorophore-labeled avidin preparations, and a counterstain with
4,6-diamidino-2-phenylindole (DAPI), sections were examined with an Olympus
BX61. A slight bleed-through from the tetramethyl rhodamine isothiocyanate
channel into the fluorescein isothiocyanate channel was visible; nevertheless, no
non-GFP-stained cells were detected as being positive for red fluorescent protein
(RFP) expression.
RESULTS
VRP replication in nasal mucosa induces opening of the
BBB. Previous studies have shown that VEE virus is able to
infect and replicate in the murine nasal neuroepithelium (6).
To confirm this observation and determine the BBB integrity
during VEE virus infection of the nasal mucosa, mice were
inoculated i.n. with 2  106 IU VRP or with diluent alone and
assayed for BBB permeability 24, 48, and 96 hpi. One hour
prior to harvest, the animals were inoculated i.p. with 800 l
1% Evans blue dye. The results showed minimal staining at 24
hpi. However, at 48 hpi after i.n. VRP inoculation, a significant
opening of the BBB throughout the brain was observed (Fig.
1), which was also confirmed with immunofluorescence studies
(data not shown). In addition, a strong preferential staining of
the frontal lobe in the area where the olfactory cortex is lo-
cated (indicated by arrows) was observed at this time point. No
staining of other areas was detectable at 96 hpi. Control ani-
mals that received i.n. diluent alone showed no signs of a
compromised BBB (Fig. 1). These data demonstrate that VRP
infection in the nasal neuroepithelium induces a breakdown of
the BBB, detectable by day 2 post-i.n. inoculation, with an
intensified staining pattern in the frontal lobe.
Intranasal inoculated VRP replicate in the nasal mucosa
but do spread into the CNS. To follow VRP RNA replication
in the CNS after intranasal inoculation, total RNA was har-
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vested from the olfactory bulbs, the cortex, and the cerebellum/
pons at 6, 12, 24, 48, and 72 hpi. After cDNA synthesis, viral
plus- and minus-strand RNA was quantified by real-time PCR,
and as shown in Fig. 2, no viral RNA replication was detectable
in the cortex or the cerebellum/pons at any of the indicated
time points. In the olfactory bulb, viral RNA replication
peaked at 12 to 24 hpi and dropped to below the detection
level by 96 hpi. Taking these findings together with previous
data that identified olfactory sensory neurons within the nasal
mucosa as the main target cells for VEE virus infection and
replication (6), it can be suggested, that (i) VRP replicate in
the nasal mucosa and (ii) VRP are able to reach the outer
layers of the olfactory bulb through the axons of actively in-
fected olfactory sensory neurons, but (iii) VRP do not spread
across the synapse connecting the OSN with second-order CNS
neurons within the olfactory bulb (Fig. 2).
Intranasal VRP inoculation induces the expression of pro-
inflammatory genes in different parts of the CNS. The upregu-
lation of certain proinflammatory cytokines and chemokines
mediates the breakdown of the BBB (23). To analyze the
induction of proinflammatory genes in the CNS by VRP infec-
tion, mice were inoculated i.n. with 2  106 IU VRP. At 6, 12,
24, 48, and 96 hpi, brains were harvested and olfactory bulbs,
cortex, and cerebellum/pons dissected for total RNA isolation.
The expression of IFN-, TNF-, and IL-6 (Fig. 3A to C) was
detectable 12 to 24 hpi in the olfactory bulbs. At 24 to 48 hpi, the
expression of those genes reached a maximum level in the
cortex. The expression levels of all 3 genes were waning by
96 hpi.
MMP-9 has an important role in maintaining the integrity of
the BBB (2, 20), and several studies have described a role of
MMP-9 in pathogenesis during viral CNS infections (15, 26,
31). As early as 12 hpi following VRP infection, increased
MMP-9 expression was detectable in the whole brain; by 48
hpi, expression reached maximal levels in the cortex, while
declining in the olfactory bulbs and the cerebellum/pons (Fig.
3D). A pattern similar to that of MMP-9 was observed for
ICAM-1 expression, a molecular marker for BBB breakdown
(23), with detectable expression by 12 hpi and 24 hpi in the
whole brain and with peak expression by 48 hpi in the cortex
(Fig. 3E). Slightly elevated expression levels were observed in
the cerebellum/pons in a temporal pattern similar to that in the
olfactory bulbs. This could be explained by the fact that the
nasal mucosa is innervated by the trigeminal nerve.
These data indicate that VRP replication in the nasal mu-
cosa induces the expression of proinflammatory genes in the
brain, as well as MMP-9 and ICAM-1, without VRP or VRP
genomes reaching the brain (16, 17, 19, 23). The expression
levels showed a temporal and spatial pattern, with maximal
expression early in the OB, followed by increased expression in
the cortex and the cerebellum/pons at later time points. The
observations suggest that cytokine signals, induced initially by
VRP infection of the olfactory sensory neurons, act in a para-
crine manner on adjunct neurons in the OB and olfactory tract.
These signals, in turn, induce the target neurons to produce a
cytokine response that operates on the next neuron as well as
other bystander cells. Ultimately, propagation of such cytokine
signals results in an early spatial pattern of BBB opening.
VRP-induced BBB opening was sufficient to enable periph-
eral VRP to enter the brain. During VEE virus infection,
opening the BBB could allow circulating virus to enter the
brain, leading to fatal encephalitis. To model this possibility,
BBB opening was induced by i.n. inoculation of VRP, and
invasion from the circulation was modeled by intravenous (i.v.)
inoculation of RFP-VRP. Mice were inoculated i.n. with 2 
FIG. 2. Viral RNA was detectable in the olfactory bulb but not in
the cortex or cerebellum/pons after i.n. VRP inoculation. At 6, 12, 24,
48, and 96 h after i.n. inoculation with 2  106 IU VRP, mice were
sacrificed and perfused, and their brains were harvested and dissected
into olfactory bulb, cortex, and cerebellum/pons for total RNA isola-
tion. Virus positive- (A) and negative-strand RNAs (B) were quanti-
fied by real-time PCR. The expression data presented are the means 

the standard errors of the means of four mice per group and represent
two independent experiments.
FIG. 1. Intranasal inoculation of VRP induces the opening of the
BBB. Mice were inoculated i.n. with 2  106 IU VRP or with diluent
alone. At 24, 48, and 96 hpi, brains of inoculated mice were harvested.
One hour before brains were harvested, mice were injected i.p. with
800 l 1% Evans blue dye (black arrows indicate strong staining in the
frontal lobe).
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106 IU VRP or diluent alone. At 24 or 48 hpi, both test and
control mice were inoculated i.v. with RFP-VRP or with dilu-
ent alone. After an additional 24 or 48 h, mice were euthanized
and brains harvested and prepared as frozen sections (Fig.
4A). Only in samples primed with VRP i.n. was RFP expres-
sion detectable in the brains at 48 hpi after intravenous RFP-
VRP injection (Fig. 4B). RFP expression was not detectable in
samples where the mice were initially inoculated i.n. with dil-
uent alone.
To exclude the possibility that the RFP-VRP proteins were
“cocarried” into the CNS by infected peripheral lymphocytes,
sections were costained for NeuN. As shown in Fig. 4B, all
RFP-expressing cells were identified as CNS neurons by posi-
tive staining for NeuN (23). This result required that RFP-
VRP cross the BBB as intact infectious virus particles and then
infect CNS neurons to allow detection of RFP expression.
Therefore, these data strongly suggest (i) that the opening of
the BBB induced by viral replication in the nasal mucosa is
sufficient to allow viral neuroinvasion from the periphery and
FIG. 3. Proinflammatory genes were expressed in different anatomical parts of the brain after i.n. VRP inoculation. Mice were inoculated with
2  106 IU VRP or diluent alone, and at 6, 12, 24, 48, and 96 hpi mice were sacrificed and their brains were harvested and dissected into olfactory
bulb, cortex, and cerebellum/pons for total RNA isolation. cDNA was synthesized, and expression levels for IFN-, TNF-, IL-6, MMP-9, and
ICAM-1 were determined by quantitative real-time PCR, normalized to GAPDH values, and analyzed in comparison to mock-infected tissue. Data
presented are the means 
 standard errors of the means for four mice per group.
FIG. 4. RFP-VRP inoculated intravenously were detectable in the
brain after VRP-induced opening of the BBB. Mice were inoculated
i.n. with 2  106 IU VRP or diluent alone. After 24 and 48 h, i.n.
VRP-inoculated mice were inoculated with 2  106 IU RFP-VRP
intravenously. (A) At 24 and 48 h post-i.v. injection of RFP-VRP, mice
were sacrificed and brains were harvested for cryoprotection. (B) After
sectioning tissues at 10 m sagitally, sections were stained for NeuN
expression and were examined by fluorescence microscopy.
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(ii) that CNS invasion by circulating virus can occur through an
open BBB.
V3000 infection opens the BBB. Previous studies have sug-
gested the involvement of the BBB in viral CNS infections. To
evaluate the status of BBB integrity during a peripheral VEE
wild-type virus infection, mice were inoculated with 103 PFU
V3000, or with diluent alone as a control, into the left rear
footpad (Fig. 5). The infected animals were then monitored for
weight loss and disease development, and brains were har-
vested daily from 1 to 7 dpi to assess BBB integrity. As shown
in Fig. 5, an increase of Evans blue dye uptake was first de-
tectable at 3 dpi. The brains were less intensely stained on 4
and 5 dpi, but by 6 dpi a second peak of BBB breakdown was
observed. The data indicated that the BBB permeability
changes during the course of V3000 infection and the opening
of the BBB shows a biphasic pattern, with maximal peaks at 3
and 6 dpi. Temporally, the first phase may correlate with prior
virus replication in the nasal neuroepithelium and the second
phase may result from invasion of and replication in the CNS.
Proinflammatory genes are expressed during peripheral
V3000 infection. A robust and rapid cytokine response has
been described during V3000 infection (12). The CNS is able
to increase cytokine expression as early as 6 to 12 h after
peripheral VRP infection in the footpad, presumably mediated
by circulating cytokines and under conditions where neither
VRP nor VRP genomes are found in the CNS (17, 29). Even
though this response is thought to set the CNS into an alerted
state, peripheral VRP replication did not cause any detectable
effect on BBB integrity (23). To study the expression levels of
TNF-, IL-6, MMP-9, and ICAM-1 (Fig. 6A to D), which were
thought to be involved in BBB opening, mice were peripherally
inoculated with 103 PFU V3000 and both serum and brains of
the infected animals were harvested for total RNA isolation
for gene expression analysis at 1 to 7 dpi. Early in the infection,
from 1 to 4 dpi, the expression levels of both TNF- and IL-6
were elevated in the serum of V3000-infected mice. By 6 dpi
levels in the serum started to decline, while expression levels in
the brain increased and remained at a plateau until the death
of the animals. These expression patterns differed from the
pattern observed for MMP-9. MMP-9 levels also increased in
the serum of the infected animals for the first 2 days of infec-
tion, but at 3 dpi MMP-9 levels started to rise in the brain. A
second peak of expression was detectable at 6 dpi. During this
late phase of infection, expression levels of MMP-9 remained
5 to 10 times higher in the brain than in the serum.
As described previously, ICAM-1 has an important role in
attachment of leukocytes to endothelial cells, and its expres-
sion is induced by TNF-, IL-1, and type I IFN (10). A
quantification of ICAM-1 expression in brains of V3000-in-
fected mice showed low levels on 1 and 2 dpi; by 3 dpi expres-
sion reached its maximum and stayed level, reflecting 10 to 15
times higher expression on 4 to 7 dpi compared to control
animals. The in vivo expression and localization of MMP-9 in
the brain of mice inoculated i.n. with 2  106 IU VRP was
studied by immunofluorescence (Fig. 6E). A strong signal for
MMP-9 expression was specifically detectable in and around
the blood vessel walls throughout the brain, suggesting that the
MMP-9 expression was localized within the brain.
Taken together, these data demonstrate that expression of
TNF- and IL-6 was induced early in the periphery during
virus infection. Expression levels increased slowly during the
early phase of virus infection but increased significantly after
the virus reached and infected the CNS, i.e., the neurotropic
phase of virus infection. The pattern observed for MMP-9
expression during V3000 infection was consistent with induc-
tion from inside the CNS, triggered by virus replication starting
by 3 dpi.
FIG. 5. Peripheral V3000 infection opened the BBB. Mice, in groups of 4 (2 representative brains are shown), were inoculated with 103 PFU
V3000 into the left rear footpad or with diluent alone as a negative control. (Top) At 1, 2, 3, 4, 5, 6, and 7 dpi, mice were injected i.p. with 800
l of 1% Evans blue dye. One hour after Evans blue dye inoculation, these mice were sacrificed and brains were examined for uptake of the dye.
(Bottom) Evans blue dye uptake in each brain sample shown as the absorbance at a wavelength of 611 nm, using the mock-treated samples as a
blank, with the left bar representing the upper brain and the right bar representing the lower brain.
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Inhibition of opening of the BBB delays disease onset. To
study the effect of a closed BBB on the course of V3000
peripheral infection, we inhibited the breakdown of the BBB
by using the MMP-9 inhibitor GM6001 (Ilomostat). Groups of
mice were treated with the inhibitor 3 h prior to infection and
at 1 and 3 dpi. At 3 and 6 dpi, treated and untreated animals
were inoculated with Evans blue dye to evaluate BBB integrity
after treatment. No BBB breakdown was detectable in treated
mice at 3 dpi compared to untreated mice (Fig. 7A). At 6 dpi
a partial inhibition of BBB breakdown in treated mice was
observed compared to untreated mice (Fig. 7A).
To evaluate the progression of disease development and
average survival time, groups of mice were treated with the
inhibitor (n 	 24; dotted line), infected, and compared to
infected but untreated control mice (n 	 8; dashed line). In-
fected untreated mice started to show signs of developing en-
cephalitis by 3 dpi (data not shown) (4, 17), and all infected but
untreated animals succumbed to viral infection between 5 and
8 dpi (Fig. 7B). Infected mice that were treated with the in-
hibitor showed an average survival time of 10 days, and by 14
dpi, 17% of the treated animals were still alive (Fig. 7B).
To ensure that the delayed onset of disease and increased
survival time was due to an inhibition of the opening of the
BBB, treated (n 	 6; dotted line) and untreated (n 	 4; dashed
line) groups of mice were inoculated with 1  102 PFU V3000
intracranially (i.c.) to bypass the BBB. As shown in Fig. 7C, no
FIG. 6. Genes involved in BBB opening were upregulated in V3000-infected mice. Mice were inoculated with 103 PFU V3000 into the left rear
footpad or with diluent alone as a negative control. Mice were sacrificed daily for 7 dpi, and serum was collected. These mice were then perfused
with 1 PBS, and brains were harvested. Mock-infected mice served as negative controls. Total RNA was isolated from sera and brains, and the
expression levels of TNF- (A), IL-6 (B), MMP-9 (C), and ICAM-1 (D; in brain samples only) were determined by quantitative real-time PCR,
normalized to GAPDH values, and analyzed in comparison to mock-infected tissue. Data presented are the means 
 standard errors of the means
for four mice per group. (E) Brains from animals inoculated i.n. with 2  106 IU VRP for 48 h were harvested for cryoprotection and sectioned
sagitally at 10 m. Sections were stained for MMP-9 and counterstained with DAPI.
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significant differences were observed between test and control
groups: treated and untreated animals showed the same course
of disease development and an average survival time of 3 to 4
days with a 100% mortality rate.
Taken together, these data indicate that the inhibition of the
BBB opening during a peripheral V3000 infection prolonged
the survival of infected mice that did succumb by 2 to 3 days,
with a 17% survival rate at 14 dpi, compared to 100% mortality
in untreated animals.
Inhibition of the opening of the BBB delayed viral neuroin-
vasion. To monitor the amount of replicating virus in MMP9-
treated and untreated mice, infections were performed as de-
scribed above. Daily, through 4 and 6 dpi, respectively, serum
and brains of V3000-infected, treated, and untreated mice
were harvested and titers were determined. Both groups of
mice developed serum viremia, with similar kinetics and titers,
with the typical peak at 3 dpi (Fig. 8A). Infected, untreated
mice (solid circles) showed typical virus replication in the
brain, with first infectious virus detectable by 24 to 48 hpi, an
increasing virus titer of up to 107 to 108 PFU/g of tissue by 4
dpi, remaining at that plateau until the animal succumbed (Fig.
8B). For the MMP-9 inhibitor-treated mice (open squares), levels
of virus were comparable to untreated mice at 1 and 2 dpi. By 3
and 4 dpi, treated mice showed waning virus titers, as they stayed
at levels of 103 PFU. An increase of virus titers up to levels of
untreated mice was observed by 5 and 6 dpi.
Together these data indicate that viral neuroinvasion is not
entirely prevented by a closed BBB, which is consistent with
the observation that virus particles initially invaded via the
olfactory neuroepithelium (Fig. 1 and 2). The usually observed
increase of viral titer by 3 dpi is significantly delayed in infected
animals in which the opening of the BBB is prevented by drug
blockade of MMP-9.
FIG. 7. Inhibition of the opening of the BBB in V3000-infected
mice delayed disease onset. Mice were treated with GM6001 3 h prior
to V3000 infection, and at 1 and 3 dpi, mice were infected with 102
PFU V3000 via injection into the rear footpad. (A) At 3 and 6 dpi,
V3000-infected animals treated with or without GM6001 were inocu-
lated i.p. with 800 l 1% Evans blue dye. One hour after Evans blue
dye injection, mice were sacrificed and brains were harvested. (B) Af-
ter infection, treated and untreated animals were monitored daily for
determination of survival time. (C) To bypass the BBB while under
GM6001 treatment, mice were infected i.c. with 102 PFU of V3000 and
monitored daily for disease development and survival rate. Red arrows
indicate time points of GM6001 administration. *, P  0.05 by log-
rank (Mantel-Cox) test.
FIG. 8. Inhibition of the opening of the BBB in V3000-infected
mice delayed viral neuroinvasion. Mice were inoculated with 102 PFU
V3000 into the left rear footpad while being treated with GM6001 or
with diluent alone as a negative control. At the indicated time points,
serum and brain samples were collected for determination of infectiv-
ity by plaque assay. Each point represents one sample, and dotted lines
represent the limit of detection. At 3 and 4 dpi, a group of 5 animals
for each time point was infected, to reach statistical significance. *,
P  0.05 by Mann-Whitney test.
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DISCUSSION
The invasion of the CNS is an important step in the patho-
genesis of neurotropic viruses. Many CNS-infecting viruses
first establish infection in the periphery before successfully
entering the brain, but the underlying details and exact path-
ways of neuroinvasion remain an active research interest (14,
22). Based on previous studies, we developed the hypothesis
that VEE virus initially enters the brain by developing a high-
titer viremia, followed by the infection of olfactory sensory
neurons, thereby gaining access to the olfactory bulbs. Then,
viral replication in the CNS induces the opening of the BBB,
which allows a second wave of invading virus from the periph-
ery to enter the CNS. Taking advantage of a well-established
mouse model system for VEE virus infection and pathogenesis
(3, 4, 13, 25) as well as the VRP system (16, 19, 23), we were
able to dissect the steps of VEE virus neuroinvasion and to
describe an important role of the BBB in VEE virus CNS
infection.
To model the early events of VEE virus neuroinvasion, we
took advantage of the well-characterized VRP system (16, 19,
23). VRP infect cells normally, undergo RNA replication, and
express marker genes, but their genomes lack the genes for the
structural proteins. Thus, they are unable to assemble new
virus particles and spread beyond the initially infected cell.
Infection with VRP allows us to directly assess possible effects
on the integrity of the BBB in the absence of virus spread to or
infection of the brain.
The first consideration in examining this hypothesis is that
VRP replicate in the nasal mucosa after i.n. inoculation with-
out spreading to the CNS. This was confirmed by the findings
that neither plus- nor minus-strand RNA is detected in the
CNS by PCR after i.n. VRP infection (Fig. 2).
Second, the temporal pattern of cytokine induction is con-
sistent with propagation of a cytokine signal along the olfactory
nerve (Fig. 3). We showed previously that VRP-infected cells
can induce a bystander cytokine response in a paracrine man-
ner (16, 23). In this study we showed that infected OSN in the
nasal mucosa send signals into the brain, where bystander cells
initiate the production of cytokines, leading to a propagating
bystander response along the olfactory nerve. At this point, we
can only speculate about the composition of bystander cells,
which could be CNS neurons, astrocytes, and microglia cells or
a combination thereof. Cytokine induction is observed first in
the olfactory bulb and later in the cortex in the absence of viral
replication at that site (Fig. 2 and 3).
Third, gene expression profiles of markers associated with
BBB opening, like ICAM-1, and inducers of BBB opening, like
TNF- and MMP-9, are upregulated in the olfactory bulb and
cortex by i.n. infection with VRP (Fig. 3). In addition, the
temporal pattern of expression is consistent with propagation
of a bystander cytokine signal along the olfactory nerve.
Fourth, the spatial and temporal aspects of BBB opening are
consistent with our hypothesis. In the brain, focal opening of
the BBB was first observed in the cortical areas associated with
olfactory tracts, followed by a more general opening of the
BBB throughout the brain (Fig. 1). This observation is consis-
tent with an initial cytokine signal reaching the brain along the
olfactory nerve.
Therefore, the observation by Charles et al. (6) that an in
situ hybridization signal in the brain was first detected in ol-
factory tracts is consistent with (i) transsynaptic spread of virus
along the olfactory nerve from the nose to the CNS as well as
(ii) transsynaptic signaling along the olfactory nerve leading to
focal opening of the BBB and consequent invasion of the brain
at that site by virus from the circulation. The latter was dem-
onstrated by infecting mice with VRP i.n. and then demon-
strating infection of neurons in the brain after i.v. inoculation
of RFP-VRP (Fig. 4). In the absence of a previous i.n. infec-
tion, which would induce opening of the BBB, RFP-VRP did
not cross into the brain. These data also show that RFP-VRP
invasion of the brain was not due to the entry of VRP-infected
cells from the periphery, nor was an infection of endothelial
cells by VRP observed.
Finally, cytokine signaling along the olfactory nerve seems
highly relevant to VEE disease, as inhibitor studies suggest
that blocking the opening of the BBB delays neuroinvasion and
in some instances prevents the development of lethal disease
(Fig. 7 and 8).
To further investigate the involvement of the BBB during neu-
roinvasion, we studied its role during peripheral (footpad) VEE
wild-type virus infection. BBB integrity was compromised during
infection and showed maximal opening at 3 dpi, the time point
when the viral load in the CNS first increases (Fig. 5); viremia was
still at a high level then and at 6 dpi, the time when cells of the
adaptive immune system enter the infected brain (4).
Previous studies have shown that the inhibition of MMP-9
activity prevents the breakdown of the BBB and severe pathol-
ogy in West Nile virus (WNV) infection (26). MMP-9 has been
described to have an important role in maintaining BBB in-
tegrity and to be involved in neuroinvasion by WNV (20, 26).
In this study, there is a significant upregulation of MMP-9 in
the brain after intranasal VRP inoculation and early during
peripheral VEE virus infection (Fig. 3 and 6). Later in infec-
tion, entering neutrophils from the periphery are also potential
alternative sources of activated membrane-associated MMP-9
(30). In any event, MMP-9 expression was specifically detect-
able by immunofluorescence staining at 2 dpi in endothelial
cells around brain blood vessels (Fig. 6E), indicating the activ-
ity of this enzyme within the brain was most likely responsible
for BBB opening. The treatment of VEE virus-infected mice
with the MMP-9 inhibitor prevented the opening of BBB
at 3 dpi, and BBB opening was significantly diminished at 6
dpi (Fig. 7). Importantly, a significant delay in onset of
disease was observed in animals treated with the MMP-9
inhibitor, which was correlated with a significant delay in
neuroinvasion (Fig. 8), resulting in an increase of the aver-
age survival time by 2 to 3 days (Fig. 7).
Several additional points of interest flow from this work.
First, inhibition of BBB opening during the first stages of
infection resulted in an increase in average survival time by 2
to 3 days, and decreased mortality. It is interesting to speculate
whether a more dramatic increase in survival may have re-
sulted from long-term treatment with the MMP-9 inhibitor.
Second, neuroinvasion during VEE virus infection could
occur by one or more of three mechanisms: (i) direct progres-
sion across synapses from the OSN to olfactory CNS neurons,
(ii) transmission of a cytokine signal to CNS olfactory tracts
resulting in local opening of the BBB and consequent local
invasion of the CNS from the circulation, and/or (iii) global
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opening of the BBB after initial CNS infection followed by
entry of circulating virus. The MMP-9 inhibitor theoretically
should not have affected transsynaptic virus transmission from
OSN along the olfactory nerve to the CNS. Detailed examina-
tion of this pathway in the presence of the inhibitor will deter-
mine whether virus or only the cytokine signal is transmitted.
Third, inhibition of BBB opening is likely to reduce entry of
cells involved in the adaptive immune response. This could
result in both a reduction in the beneficial effects of the im-
mune response or in potentially immunopathogenic effects,
thereby complicating the interpretation of experiments with
the MMP-9 inhibitor.
Fourth, is the initial invasion of the brain sufficient for mor-
tality? Clearly, inhibition of BBB opening early in infection
reduces mortality and morbidity, but ascribing this effect to a
specific event must await definition of early and late neuroin-
vasion and experimental differentiation between them. How-
ever, differences in degree and timing of BBB opening could
account for species-specific differences in susceptibility to le-
thal VEE virus encephalitis. For instance, encephalitis occurs
in 100% of mice, 30 to 70% of equines, and  4% of humans.
Finally, although we cannot assume that the neuroinvasion
mechanism defined here may apply to VEE virus infection in
humans, it may be possible to utilize intranasal infection with
VRP to transiently open the BBB for treatment of CNS dis-
ease or otherwise-untreatable tumors. Antibodies and approx-
imately 98% of small-molecule drugs are prevented from en-
tering the CNS due to the BBB, thus complicating and severely
reducing treatment options for life-threatening infections and
tumors of the CNS (8, 9).
In summary, we have presented a modified hypothesis regard-
ing neuroinvasion and neuropathogenesis during VEE virus in-
fection of the mouse. The first neurons infected are OSN, where
unmyelinated nerves and fenestrated capillaries in the nose are
anatomically juxtaposed, allowing neuronal infection by virus cir-
culating in the blood. Viral replication in OSN induces a cytokine
signal that is transmitted across synapses to olfactory tracts in the
brain, causing local opening of the BBB and local invasion from
the circulation directly into the CNS. Alternatively, or in addition,
virus itself moves up the olfactory nerve to the CNS. Either or
both pathways result in an initial seeding of the CNS, amplified
cytokine signaling, widespread breakdown of the BBB, and con-
sequent invasion of circulating virus. Blocking the opening of the
BBB early after subcutaneous infection could restrict initial local
seeding of the brain, the more widespread second phase of neu-
roinvasion, and the resulting morbidity and mortality character-
istic of VEE virus infection.
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